Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
F-box and leucine-rich repeat protein 14 (FBXL14)
- Target
- FBXL14
- Molecular classification
- E3 ubiquitin ligase (SCF complex member), F-box protein family, Leucine-rich repeat (LRR) protein
01
Overview
FBXL14 is an F-box protein containing leucine-rich repeats that functions as the substrate-recognition module of SCF (SKP1–CUL1–F-box protein) E3 ubiquitin ligase complexes. It plays a critical role in marking proteins such as HES1, SNAI1, and Mkp3 for ubiquitin-mediated degradation, thereby regulating neuronal differentiation, cell fate decisions, and embryonic axis formation. In cancer biology, FBXL14 is implicated in the degradation of proteins that control cell migration and epithelial-mesenchymal transition, with its downregulation associated with tumor progression and chemoresistance. Disruption of FBXL14 function modulates key developmental genes and may have therapeutic relevance, although no drugs directly targeting FBXL14 have been reported to date.
- Other names
- FBXL14F-box/LRR-repeat protein 14FBL14MGC40195Fbl14F-box and leucine rich repeat protein 14
02
Mechanism of action
Drugs/treatments affecting FBXL14 would likely modulate its E3 ligase activity, impacting substrate protein degradation, notably HES1, SNAI1, Mkp3
03
Biological functions
Ubiquitin-dependent proteolysis (targeting proteins for degradation)Regulation of neuronal differentiation (by degrading HES1)Regulation of cell fate and development (including axis patterning)Control of protein stability (e.g., SNAI1, Mkp3)
04
Disease associations
Cancer (FBXL14 downregulation linked to increased SNAI1 protein and tumor progression)Chemoresistance (through Mkp3 modulation)Developmental disorders (regulation of axis formation and neural crest development)
05
Safety considerations
Potential off-target effects due to the central role of ubiquitin-mediated proteolysis in diverse cellular processesDisruption could lead to misregulation of development, cell cycle, or differentiation, possibly causing cancer, developmental disorders, or undesired cell fates
06
Biomarkers
Downregulation of FBXL14 may serve as a biomarker for tumor progression, especially linked to hypoxia and increased SNAI1 protein levelsExpression levels of FBXL14 and its substrates (HES1, SNAI1, Mkp3) may provide insight into disease states or cell differentiation status
Beyond the preview
Go deeper on F-box and leucine-rich repeat protein 14 (FBXL14).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on F-box and leucine-rich repeat protein 14 (FBXL14).